News
Despite near universal availability of nirsevimab, only 35% of eligible children receive nirsevimab for RSV prophylaxis.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback